Naqvi Nawazish, Iismaa Siiri E, Graham Robert M, Husain Ahsan
Division of Cardiology, Department of Medicine, Emory University School of Medicine, Atlanta, GA, United States.
Victor Chang Cardiac Research Institute, Darlinghurst, NSW, Australia.
Front Cell Dev Biol. 2021 Oct 11;9:747842. doi: 10.3389/fcell.2021.747842. eCollection 2021.
Heart failure in adults is a leading cause of morbidity and mortality worldwide. It can arise from a variety of diseases, with most resulting in a loss of cardiomyocytes that cannot be replaced due to their inability to replicate, as well as to a lack of resident cardiomyocyte progenitor cells in the adult heart. Identifying and exploiting mechanisms underlying loss of developmental cardiomyocyte replicative capacity has proved to be useful in developing therapeutics to effect adult cardiac regeneration. Of course, effective regeneration of myocardium after injury requires not just expansion of cardiomyocytes, but also neovascularization to allow appropriate perfusion and resolution of injury-induced inflammation and interstitial fibrosis, but also reversal of adverse left ventricular remodeling. In addition to overcoming these challenges, a regenerative therapy needs to be safe and easily translatable. Failure to address these critical issues will delay the translation of regenerative approaches. This review critically analyzes current regenerative approaches while also providing a framework for future experimental studies aimed at enhancing success in regenerating the injured heart.
成人心力衰竭是全球发病和死亡的主要原因。它可由多种疾病引起,大多数疾病会导致心肌细胞丧失,由于其无法复制,以及成年心脏中缺乏驻留的心肌祖细胞,这些心肌细胞无法被替代。事实证明,识别和利用发育中心肌细胞复制能力丧失的潜在机制,有助于开发实现成体心脏再生的治疗方法。当然,损伤后心肌的有效再生不仅需要心肌细胞的扩增,还需要新血管形成,以实现适当的灌注,消除损伤诱导的炎症和间质纤维化,同时逆转不良的左心室重构。除了克服这些挑战外,再生疗法还需要安全且易于转化应用。未能解决这些关键问题将延迟再生方法的转化应用。本综述批判性地分析了当前的再生方法,同时也为未来旨在提高受损心脏再生成功率的实验研究提供了一个框架。